间充质干细胞联合血小板生成素受体激动剂在异基因造血干细胞移植后血小板恢复中的研究进展

Advances in mesenchymal stem cells combined with thrombopoietin receptor agonists in platelet recovery after allogeneic hematopoietic stem cell transplantation

异基因造血干细胞移植(allo-HSCT)是治愈血液系统疾病的一种有效方法。血小板减少是allo-HSCT后常见且严重的并发症,与预后不良相关。成分血输注、促进血小板生成及释放药物、糖皮质激素等可用于allo-HSCT后血小板减少的治疗,但疗效有限。近年来,随着对allo-HSCT后血小板减少发病机制的研究,间充质干细胞(MSCs)及血小板生成素受体激动剂(TPO-RA)已作为其治疗选择,且证明安全有效。本文就MSCs联合TPO-RA在allo-HSCT后血小板恢复中的作用机制及安全性和有效性进行综述。

Allogeneic hematopoietic stem cell transplantation(allo-HSCT)is an effective method to cure hematological diseases.Thrombocytopenia associated with a poor prognosis is a common but severe complication after allo-HSCT.Blood component transfusion,drugs that promote platelet production and release,and glucocorticoids can treat thrombocytopenia after allo-HSCT,but the efficacy is limited.In recent years,with the study of the pathogenesis of thrombocytopenia after allo-HSCT,mesenchymal stem cells(MSCs)and thrombopoietin receptor agonists(TPO-RA)have been used as their treatment options and have proved to be safe and effective.This article reviews the mechanism of action,safety and efficacy of MSCs combined with TPO-RA in platelet recovery after allo-HSCT.